Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020 | Published in healthbook TIMES Oncology Hematology
Frontiers | Retrospective Comparative Analysis of KRAS G12C vs. Other KRAS Mutations in mCRC Patients Treated With First-Line Chemotherapy Doublet + Bevacizumab
Sotorasib shows activity in advanced colorectal cancer with KRAS G12C mutation
Tumor microenvironment-adjusted prognostic implications of the KRAS mutation subtype in patients with stage III colorectal cancer treated with adjuvant FOLFOX | Scientific Reports
Chemically modified MIR143-3p exhibited anti-cancer effects by impairing the KRAS network in colorectal cancer cells: Molecular Therapy - Nucleic Acids
Clinical characteristics and prognostic value of the KRAS mutation in Chinese colorectal cancer patients - Ye Yuan, Yingting Liu, Ye Wu, Junling Zhang, Chunti Shen, Feng Zhang, Changping Wu, Wenwei Hu, 2021
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer | Semantic Scholar
Cells | Free Full-Text | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study
Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer | Molecular Cancer | Full Text
KRAS testing is a screening of non-responders to anti-EGFR therapy.... | Download Scientific Diagram
IJMS | Free Full-Text | Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients | Nature Communications
The current treatment paradigm for patients with metastatic colorectal... | Download Scientific Diagram
The current understanding on the impact of KRAS on colorectal cancer - ScienceDirect
Promising results for a new bowel cancer treatment
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C | NEJM
KRAS-Targeted Therapy Doubles as Component of Immunotherapy - NCI
KRAS mutation: from undruggable to druggable in cancer | Signal Transduction and Targeted Therapy
IJMS | Free Full-Text | Prognostic and Predictive Roles of KRAS Mutation in Colorectal Cancer
KRAS mutation in patients with metastatic colorectal cancer does not preclude benefit from oxaliplatin‑ or irinotecan‑based treatment
Correlation between KRAS, NRAS and BRAF mutations and tumor localizations in patients with primary and metastatic colorectal cancer
Colorectal Cancer – Treatments | Gastrointestinal Cancer
Colorectal Cancer
Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. | Semantic Scholar
Study reveals potential target for precision colorectal cancer treatment - Redox Medicine Society
Biomedicines | Free Full-Text | Identifying Novel Actionable Targets in Colon Cancer
KRAS Mutation in Colon Cancer: A Marker of Resistance to EGFR-I Therapy | Annals of Surgical Oncology
Can KRAS Positive Colorectal and Lung Cancer Finally be Targeted? - CancerConnect
